JP2016503803A5 - - Google Patents

Download PDF

Info

Publication number
JP2016503803A5
JP2016503803A5 JP2015549792A JP2015549792A JP2016503803A5 JP 2016503803 A5 JP2016503803 A5 JP 2016503803A5 JP 2015549792 A JP2015549792 A JP 2015549792A JP 2015549792 A JP2015549792 A JP 2015549792A JP 2016503803 A5 JP2016503803 A5 JP 2016503803A5
Authority
JP
Japan
Prior art keywords
weight percent
amount
glatiramer acetate
oral tablet
hydroxypropylcellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015549792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503803A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/077034 external-priority patent/WO2014100639A1/en
Publication of JP2016503803A publication Critical patent/JP2016503803A/ja
Publication of JP2016503803A5 publication Critical patent/JP2016503803A5/ja
Withdrawn legal-status Critical Current

Links

JP2015549792A 2012-12-21 2013-12-20 酢酸グラチラマーの経粘膜送達 Withdrawn JP2016503803A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745226P 2012-12-21 2012-12-21
US61/745,226 2012-12-21
PCT/US2013/077034 WO2014100639A1 (en) 2012-12-21 2013-12-20 Transmucosal delivery of glatiramer acetate

Publications (2)

Publication Number Publication Date
JP2016503803A JP2016503803A (ja) 2016-02-08
JP2016503803A5 true JP2016503803A5 (https=) 2017-02-02

Family

ID=50979257

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015549792A Withdrawn JP2016503803A (ja) 2012-12-21 2013-12-20 酢酸グラチラマーの経粘膜送達

Country Status (15)

Country Link
US (1) US20160193276A1 (https=)
EP (1) EP2934492A4 (https=)
JP (1) JP2016503803A (https=)
KR (1) KR20150111918A (https=)
CN (1) CN104869983A (https=)
AU (1) AU2013361053A1 (https=)
BR (1) BR112015014095A2 (https=)
CA (1) CA2895359A1 (https=)
EA (1) EA201591188A1 (https=)
HK (2) HK1214134A1 (https=)
IL (1) IL239280A0 (https=)
MX (1) MX2015007678A (https=)
SG (1) SG11201504422XA (https=)
WO (1) WO2014100639A1 (https=)
ZA (1) ZA201505049B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ703122A (en) 2010-10-11 2016-06-24 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
KR20140101730A (ko) 2011-10-10 2014-08-20 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
WO2015140790A1 (en) 2014-03-17 2015-09-24 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
CN106924175B (zh) * 2015-12-29 2020-07-03 深圳翰宇药业股份有限公司 一种治疗多发性硬化症的药物组合物
HK1257053A1 (zh) * 2016-02-12 2019-10-11 特一华制药株式会社 干法制粒物和含有该干法制粒物的固态制剂及它的制造方法
JP2020525459A (ja) 2017-06-26 2020-08-27 アンスティテュ・パストゥール Hivリザーバーを排除し、ウイルス負荷を低減する処置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022663B2 (en) * 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
WO2001060392A1 (en) * 2000-02-18 2001-08-23 Yeda Research And Development Co., Ltd. At The Weizmann Institute Of Science Oral, nasal and pulmonary dosage formualtions of copolymer 1
IL159715A0 (en) * 2001-07-10 2004-06-20 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
PL1848415T3 (pl) * 2005-02-17 2013-10-31 Teva Pharma Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego
WO2007061415A1 (en) * 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of telmisartan
JP2009521523A (ja) * 2005-12-27 2009-06-04 ジュビラント・オルガノシス・リミテッド 口中溶解性医薬組成物およびその製造方法
BRPI0622054B8 (pt) * 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
ES2329327B1 (es) * 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.

Similar Documents

Publication Publication Date Title
JP2016503803A5 (https=)
CA2251886C (en) An oral pharmaceutical formulation containing ibandronate
Sharma et al. A comprehensive review on fast dissolving tablet technology
JP2006505566A5 (https=)
JP2016516698A5 (https=)
JP2011509295A5 (https=)
JP2016522191A (ja) ロスバスタチンまたはその薬学的に許容可能な塩を含有する膜コーティング層を含む複合製剤
JP2014221827A5 (https=)
JP2018521985A5 (https=)
SI3106148T1 (en) ORODISPERSIBILITY DOSING UNIT, CONTAINING ESTETROL COMPONENT
JP5810819B2 (ja) 積層錠
SI2760821T1 (en) A salt salt of an anti-inflammatory substituted cyclobutenedione compound
TWI480067B (zh) 經包衣之固體製劑
JP2018118966A5 (https=)
RU2018137590A (ru) Фармацевтические композиции для производного n-пропаргиламина
CA2648538A1 (en) Oral rapid release pharmaceutical formulation for pyridylmethylsulfinyl-benzimidazoles
CN102958522B (zh) 微粒包衣制剂
JPH05246845A (ja) イブプロフェン含有解熱鎮痛剤
JP2015521647A5 (https=)
JP2010241760A (ja) 不快な味の軽減された口腔内速崩壊錠及びその製造方法
JP2010168287A (ja) 内服用錠剤
WO2015008825A1 (ja) 口腔内崩壊錠
JP2017511350A5 (https=)
JP2010509293A5 (https=)
JPWO2006046527A1 (ja) 口腔内溶解用固形製剤